Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 311

1.

Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels.

Sitohy B, Chang S, Sciuto TE, Masse E, Shen M, Kang PM, Jaminet SC, Benjamin LE, Bhatt RS, Dvorak AM, Nagy JA, Dvorak HF.

Am J Pathol. 2017 Oct;187(10):2337-2347. doi: 10.1016/j.ajpath.2017.06.010. Epub 2017 Jul 21.

PMID:
28736316
2.

Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.

Bridgeman VL, Vermeulen PB, Foo S, Bilecz A, Daley F, Kostaras E, Nathan MR, Wan E, Frentzas S, Schweiger T, Hegedus B, Hoetzenecker K, Renyi-Vamos F, Kuczynski EA, Vasudev NS, Larkin J, Gore M, Dvorak HF, Paku S, Kerbel RS, Dome B, Reynolds AR.

J Pathol. 2017 Feb;241(3):362-374. doi: 10.1002/path.4845. Epub 2016 Dec 29.

3.

Stromal-Based Signatures for the Classification of Gastric Cancer.

Uhlik MT, Liu J, Falcon BL, Iyer S, Stewart J, Celikkaya H, O'Mahony M, Sevinsky C, Lowes C, Douglass L, Jeffries C, Bodenmiller D, Chintharlapalli S, Fischl A, Gerald D, Xue Q, Lee JY, Santamaria-Pang A, Al-Kofahi Y, Sui Y, Desai K, Doman T, Aggarwal A, Carter JH, Pytowski B, Jaminet SC, Ginty F, Nasir A, Nagy JA, Dvorak HF, Benjamin LE.

Cancer Res. 2016 May 1;76(9):2573-86. doi: 10.1158/0008-5472.CAN-16-0022.

4.

Intracellular distribution of TM4SF1 and internalization of TM4SF1-antibody complex in vascular endothelial cells.

Sciuto TE, Merley A, Lin CI, Richardson D, Liu Y, Li D, Dvorak AM, Dvorak HF, Jaminet SC.

Biochem Biophys Res Commun. 2015 Sep 25;465(3):338-43. doi: 10.1016/j.bbrc.2015.07.142. Epub 2015 Aug 1.

5.

Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy.

Dvorak HF.

Cancer J. 2015 Jul-Aug;21(4):237-43. doi: 10.1097/PPO.0000000000000124. Review.

PMID:
26222073
6.

Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature.

Visintin A, Knowlton K, Tyminski E, Lin CI, Zheng X, Marquette K, Jain S, Tchistiakova L, Li D, O'Donnell CJ, Maderna A, Cao X, Dunn R, Snyder WB, Abraham AK, Leal M, Shetty S, Barry A, Zawel L, Coyle AJ, Dvorak HF, Jaminet SC.

Mol Cancer Ther. 2015 Aug;14(8):1868-76. doi: 10.1158/1535-7163.MCT-15-0188. Epub 2015 Jun 18.

7.

Tumors: wounds that do not heal-redux.

Dvorak HF.

Cancer Immunol Res. 2015 Jan;3(1):1-11. doi: 10.1158/2326-6066.CIR-14-0209. Review.

8.

Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment.

Sadow PM, Priolo C, Nanni S, Karreth FA, Duquette M, Martinelli R, Husain A, Clohessy J, Kutzner H, Mentzel T, Carman CV, Farsetti A, Henske EP, Palescandolo E, Macconaill LE, Chung S, Fadda G, Lombardi CP, De Angelis AM, Durante O, Parker JA, Pontecorvi A, Dvorak HF, Fletcher C, Pandolfi PP, Lawler J, Nucera C.

J Natl Cancer Inst. 2014 Jul 25;106(8). pii: dju182. doi: 10.1093/jnci/dju182. Print 2014 Aug.

9.

TM4SF1: a new vascular therapeutic target in cancer.

Lin CI, Merley A, Sciuto TE, Li D, Dvorak AM, Melero-Martin JM, Dvorak HF, Jaminet SC.

Angiogenesis. 2014 Oct;17(4):897-907. doi: 10.1007/s10456-014-9437-2. Epub 2014 Jul 2.

10.

The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1.

Qin L, Zhao D, Xu J, Ren X, Terwilliger EF, Parangi S, Lawler J, Dvorak HF, Zeng H.

Blood. 2013 Mar 14;121(11):2154-64. doi: 10.1182/blood-2012-07-443903. Epub 2013 Jan 11.

11.

Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets.

Nagy JA, Dvorak HF.

Clin Exp Metastasis. 2012 Oct;29(7):657-62. doi: 10.1007/s10585-012-9500-6. Epub 2012 Jun 13.

12.

Revealing the role of phospholipase Cβ3 in the regulation of VEGF-induced vascular permeability.

Hoeppner LH, Phoenix KN, Clark KJ, Bhattacharya R, Gong X, Sciuto TE, Vohra P, Suresh S, Bhattacharya S, Dvorak AM, Ekker SC, Dvorak HF, Claffey KP, Mukhopadhyay D.

Blood. 2012 Sep 13;120(11):2167-73. doi: 10.1182/blood-2012-03-417824. Epub 2012 Jun 6.

13.

Anti-VEGF/VEGFR therapy for cancer: reassessing the target.

Sitohy B, Nagy JA, Dvorak HF.

Cancer Res. 2012 Apr 15;72(8):1909-14. doi: 10.1158/0008-5472.CAN-11-3406. Review.

14.

Vascular hyperpermeability, angiogenesis, and stroma generation.

Nagy JA, Dvorak AM, Dvorak HF.

Cold Spring Harb Perspect Med. 2012 Feb;2(2):a006544. doi: 10.1101/cshperspect.a006544. Review.

15.

Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy.

Sitohy B, Nagy JA, Jaminet SC, Dvorak HF.

Cancer Res. 2011 Nov 15;71(22):7021-8. doi: 10.1158/0008-5472.CAN-11-1693. Epub 2011 Sep 21.

16.

Orphan nuclear transcription factor TR3/Nur77 regulates microvessel permeability by targeting endothelial nitric oxide synthase and destabilizing endothelial junctions.

Zhao D, Qin L, Bourbon PM, James L, Dvorak HF, Zeng H.

Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):12066-71. doi: 10.1073/pnas.1018438108. Epub 2011 Jul 5.

17.

TM4SF1: a tetraspanin-like protein necessary for nanopodia formation and endothelial cell migration.

Zukauskas A, Merley A, Li D, Ang LH, Sciuto TE, Salman S, Dvorak AM, Dvorak HF, Jaminet SC.

Angiogenesis. 2011 Sep;14(3):345-54. doi: 10.1007/s10456-011-9218-0. Epub 2011 May 29.

18.

Tumor microenvironment and progression.

Dvorak HF, Weaver VM, Tlsty TD, Bergers G.

J Surg Oncol. 2011 May 1;103(6):468-74. doi: 10.1002/jso.21709. Review.

19.

Proteolytic cleavage of versican and involvement of ADAMTS-1 in VEGF-A/VPF-induced pathological angiogenesis.

Fu Y, Nagy JA, Brown LF, Shih SC, Johnson PY, Chan CK, Dvorak HF, Wight TN.

J Histochem Cytochem. 2011 May;59(5):463-73. doi: 10.1369/0022155411401748. Epub 2011 Mar 16.

20.

A multi-gene transcriptional profiling approach to the discovery of cell signature markers.

Wada Y, Li D, Merley A, Zukauskas A, Aird WC, Dvorak HF, Shih SC.

Cytotechnology. 2011 Jan;63(1):25-33. doi: 10.1007/s10616-010-9315-8. Epub 2010 Oct 23.

21.

My friend Marty.

Dvorak HF.

J Cutan Pathol. 2010 Apr;37 Suppl 1:6-7. doi: 10.1111/j.1600-0560.2010.01500.x. No abstract available.

PMID:
20482669
22.

Heterogeneity of the tumor vasculature.

Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF.

Semin Thromb Hemost. 2010 Apr;36(3):321-31. doi: 10.1055/s-0030-1253454. Epub 2010 May 20. Review.

23.

Vascular permeability to plasma, plasma proteins, and cells: an update.

Dvorak HF.

Curr Opin Hematol. 2010 May;17(3):225-9. doi: 10.1097/MOH.0b013e3283386638. Review.

24.

Vascular permeability and pathological angiogenesis in caveolin-1-null mice.

Chang SH, Feng D, Nagy JA, Sciuto TE, Dvorak AM, Dvorak HF.

Am J Pathol. 2009 Oct;175(4):1768-76. doi: 10.2353/ajpath.2009.090171. Epub 2009 Sep 3.

25.

Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level.

Zhang X, Kazerounian S, Duquette M, Perruzzi C, Nagy JA, Dvorak HF, Parangi S, Lawler J.

FASEB J. 2009 Oct;23(10):3368-76. doi: 10.1096/fj.09-131649. Epub 2009 Jun 15.

26.

Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase.

Xue Q, Nagy JA, Manseau EJ, Phung TL, Dvorak HF, Benjamin LE.

Arterioscler Thromb Vasc Biol. 2009 Aug;29(8):1172-8. doi: 10.1161/ATVBAHA.109.185918. Epub 2009 May 14.

27.

VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation.

Chang SH, Kanasaki K, Gocheva V, Blum G, Harper J, Moses MA, Shih SC, Nagy JA, Joyce J, Bogyo M, Kalluri R, Dvorak HF.

Cancer Res. 2009 May 15;69(10):4537-44. doi: 10.1158/0008-5472.CAN-08-4539. Epub 2009 May 12.

28.

The L6 protein TM4SF1 is critical for endothelial cell function and tumor angiogenesis.

Shih SC, Zukauskas A, Li D, Liu G, Ang LH, Nagy JA, Brown LF, Dvorak HF.

Cancer Res. 2009 Apr 15;69(8):3272-7. doi: 10.1158/0008-5472.CAN-08-4886. Epub 2009 Apr 7.

29.

Why are tumour blood vessels abnormal and why is it important to know?

Nagy JA, Chang SH, Dvorak AM, Dvorak HF.

Br J Cancer. 2009 Mar 24;100(6):865-9. doi: 10.1038/sj.bjc.6604929. Epub 2009 Feb 24. Review.

30.

Chapter 3. The adenoviral vector angiogenesis/lymphangiogenesis assay.

Nagy JA, Shih SC, Wong WH, Dvorak AM, Dvorak HF.

Methods Enzymol. 2008;444:43-64. doi: 10.1016/S0076-6879(08)02803-6.

PMID:
19007660
31.

Vascular permeability, vascular hyperpermeability and angiogenesis.

Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF.

Angiogenesis. 2008;11(2):109-19. doi: 10.1007/s10456-008-9099-z. Epub 2008 Feb 22. Review.

32.

VEGF-A and the induction of pathological angiogenesis.

Nagy JA, Dvorak AM, Dvorak HF.

Annu Rev Pathol. 2007;2:251-75. Review.

PMID:
18039100
33.

Transcellular diapedesis is initiated by invasive podosomes.

Carman CV, Sage PT, Sciuto TE, de la Fuente MA, Geha RS, Ochs HD, Dvorak HF, Dvorak AM, Springer TA.

Immunity. 2007 Jun;26(6):784-97.

34.

Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting.

Wirzenius M, Tammela T, Uutela M, He Y, Odorisio T, Zambruno G, Nagy JA, Dvorak HF, Ylä-Herttuala S, Shibuya M, Alitalo K.

J Exp Med. 2007 Jun 11;204(6):1431-40. Epub 2007 May 29.

35.

Down syndrome candidate region 1 isoform 1 mediates angiogenesis through the calcineurin-NFAT pathway.

Qin L, Zhao D, Liu X, Nagy JA, Hoang MV, Brown LF, Dvorak HF, Zeng H.

Mol Cancer Res. 2006 Nov;4(11):811-20.

36.

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.

Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, Sun J, Monahan-Earley RA, Shiojima I, Nagy JA, Lin MI, Walsh K, Dvorak AM, Briscoe DM, Neeman M, Sessa WC, Dvorak HF, Benjamin LE.

Cancer Cell. 2006 Aug;10(2):159-70.

37.

Permeability properties of tumor surrogate blood vessels induced by VEGF-A.

Nagy JA, Feng D, Vasile E, Wong WH, Shih SC, Dvorak AM, Dvorak HF.

Lab Invest. 2006 Aug;86(8):767-80. Epub 2006 May 29.

38.

Orphan nuclear receptor TR3/Nur77 regulates VEGF-A-induced angiogenesis through its transcriptional activity.

Zeng H, Qin L, Zhao D, Tan X, Manseau EJ, Van Hoang M, Senger DR, Brown LF, Nagy JA, Dvorak HF.

J Exp Med. 2006 Mar 20;203(3):719-29. Epub 2006 Mar 6.

39.

Discovery of vascular permeability factor (VPF).

Dvorak HF.

Exp Cell Res. 2006 Mar 10;312(5):522-6. Epub 2006 Jan 20. Review. No abstract available.

PMID:
16430882
40.

Angiogenesis: update 2005.

Dvorak HF.

J Thromb Haemost. 2005 Aug;3(8):1835-42. Review.

41.

Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin.

Satchi-Fainaro R, Mamluk R, Wang L, Short SM, Nagy JA, Feng D, Dvorak AM, Dvorak HF, Puder M, Mukhopadhyay D, Folkman J.

Cancer Cell. 2005 Mar;7(3):251-61.

42.

VEGF-A angiogenesis induces a stable neovasculature in adult murine brain.

Stiver SI, Tan X, Brown LF, Hedley-Whyte ET, Dvorak HF.

J Neuropathol Exp Neurol. 2004 Aug;63(8):841-55.

PMID:
15330339
43.

Ultrastructural localization of platelet endothelial cell adhesion molecule (PECAM-1, CD31) in vascular endothelium.

Feng D, Nagy JA, Pyne K, Dvorak HF, Dvorak AM.

J Histochem Cytochem. 2004 Jan;52(1):87-101.

PMID:
14688220
44.

VEGF-A induces angiogenesis, arteriogenesis, lymphangiogenesis, and vascular malformations.

Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Manseau EJ, Dvorak AM, Dvorak HF.

Cold Spring Harb Symp Quant Biol. 2002;67:227-37. No abstract available.

PMID:
12858545
45.

T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema.

Schacht V, Ramirez MI, Hong YK, Hirakawa S, Feng D, Harvey N, Williams M, Dvorak AM, Dvorak HF, Oliver G, Detmar M.

EMBO J. 2003 Jul 15;22(14):3546-56.

46.

VEGF-A(164/165) and PlGF: roles in angiogenesis and arteriogenesis.

Nagy JA, Dvorak AM, Dvorak HF.

Trends Cardiovasc Med. 2003 Jul;13(5):169-75. Review.

PMID:
12837578
47.

Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma.

Dvorak HF.

Am J Pathol. 2003 Jun;162(6):1747-57. No abstract available.

48.

Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis.

Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Detmar MJ, Lawitts JA, Benjamin L, Tan X, Manseau EJ, Dvorak AM, Dvorak HF.

J Exp Med. 2002 Dec 2;196(11):1497-506.

50.

Defective associations between blood vessels and brain parenchyma lead to cerebral hemorrhage in mice lacking alphav integrins.

McCarty JH, Monahan-Earley RA, Brown LF, Keller M, Gerhardt H, Rubin K, Shani M, Dvorak HF, Wolburg H, Bader BL, Dvorak AM, Hynes RO.

Mol Cell Biol. 2002 Nov;22(21):7667-77.

Supplemental Content

Loading ...
Support Center